Low direct cytotoxicity of nabumetone on gastric mucosal cells

Yasuhiro Arai, Ken Ichiro Tanaka, Hironori Ushijima, Wataru Tomisato, Shinji Tsutsumi, Mayuko Aburaya, Tatsuya Hoshino, Kazumi Yokomizo, Keitarou Suzuki, Takashi Katsu, Tomofusa Tsuchiya, Tohru Mizushima

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Prodrugs of non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for clinical purposes because they are not harmful to the gastrointestinal mucosa. We recently showed that NSAIDs have direct cytotoxicity in NSAID-induced gastric lesions. We show here that under conditions where the NSAIDs indomethacin and celecoxib clearly induce cell death, an NSAID prodrug, nabumetone, and its active metabolite 6-methoxy-2-naphthylacetic acid (6MNA), did not have such effects. Moreover, nabumetone and 6MNA exhibited much lower membrane permeabilizing activities than did indomethacin and celecoxib. We recently reported that when an orally administered NSAID was used in combination with a low dose of intravenously administered indomethacin, the severity of gastric lesions produced in rats depended on the cytotoxicity of the orally administered NSAID. Using a similar protocol, we show here that gastric lesions were produced when the orally administered NSAID was celecoxib, but not when nabumetone was used. We thus propose that the low direct cytotoxicity of nabumetone observed in vitro is maintained in vivo, and that the use of nabumetone does not harm the gastric mucosa.

Original languageEnglish
Pages (from-to)1641-1646
Number of pages6
JournalDigestive Diseases and Sciences
Volume50
Issue number9
DOIs
Publication statusPublished - 2005 Sep
Externally publishedYes

Fingerprint

nabumetone
Celecoxib
Stomach
Anti-Inflammatory Agents
Pharmaceutical Preparations
Indomethacin
Prodrugs
Gastrointestinal Agents
Gastric Mucosa

Keywords

  • Gastric lesions
  • Gastric mucosal cells
  • Membrane permeabilization
  • Nabumetone

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Arai, Y., Tanaka, K. I., Ushijima, H., Tomisato, W., Tsutsumi, S., Aburaya, M., ... Mizushima, T. (2005). Low direct cytotoxicity of nabumetone on gastric mucosal cells. Digestive Diseases and Sciences, 50(9), 1641-1646. https://doi.org/10.1007/s10620-005-2909-x

Low direct cytotoxicity of nabumetone on gastric mucosal cells. / Arai, Yasuhiro; Tanaka, Ken Ichiro; Ushijima, Hironori; Tomisato, Wataru; Tsutsumi, Shinji; Aburaya, Mayuko; Hoshino, Tatsuya; Yokomizo, Kazumi; Suzuki, Keitarou; Katsu, Takashi; Tsuchiya, Tomofusa; Mizushima, Tohru.

In: Digestive Diseases and Sciences, Vol. 50, No. 9, 09.2005, p. 1641-1646.

Research output: Contribution to journalArticle

Arai, Y, Tanaka, KI, Ushijima, H, Tomisato, W, Tsutsumi, S, Aburaya, M, Hoshino, T, Yokomizo, K, Suzuki, K, Katsu, T, Tsuchiya, T & Mizushima, T 2005, 'Low direct cytotoxicity of nabumetone on gastric mucosal cells', Digestive Diseases and Sciences, vol. 50, no. 9, pp. 1641-1646. https://doi.org/10.1007/s10620-005-2909-x
Arai Y, Tanaka KI, Ushijima H, Tomisato W, Tsutsumi S, Aburaya M et al. Low direct cytotoxicity of nabumetone on gastric mucosal cells. Digestive Diseases and Sciences. 2005 Sep;50(9):1641-1646. https://doi.org/10.1007/s10620-005-2909-x
Arai, Yasuhiro ; Tanaka, Ken Ichiro ; Ushijima, Hironori ; Tomisato, Wataru ; Tsutsumi, Shinji ; Aburaya, Mayuko ; Hoshino, Tatsuya ; Yokomizo, Kazumi ; Suzuki, Keitarou ; Katsu, Takashi ; Tsuchiya, Tomofusa ; Mizushima, Tohru. / Low direct cytotoxicity of nabumetone on gastric mucosal cells. In: Digestive Diseases and Sciences. 2005 ; Vol. 50, No. 9. pp. 1641-1646.
@article{6ebe1555589a4a10b66dd7bc9ed0216b,
title = "Low direct cytotoxicity of nabumetone on gastric mucosal cells",
abstract = "Prodrugs of non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for clinical purposes because they are not harmful to the gastrointestinal mucosa. We recently showed that NSAIDs have direct cytotoxicity in NSAID-induced gastric lesions. We show here that under conditions where the NSAIDs indomethacin and celecoxib clearly induce cell death, an NSAID prodrug, nabumetone, and its active metabolite 6-methoxy-2-naphthylacetic acid (6MNA), did not have such effects. Moreover, nabumetone and 6MNA exhibited much lower membrane permeabilizing activities than did indomethacin and celecoxib. We recently reported that when an orally administered NSAID was used in combination with a low dose of intravenously administered indomethacin, the severity of gastric lesions produced in rats depended on the cytotoxicity of the orally administered NSAID. Using a similar protocol, we show here that gastric lesions were produced when the orally administered NSAID was celecoxib, but not when nabumetone was used. We thus propose that the low direct cytotoxicity of nabumetone observed in vitro is maintained in vivo, and that the use of nabumetone does not harm the gastric mucosa.",
keywords = "Gastric lesions, Gastric mucosal cells, Membrane permeabilization, Nabumetone",
author = "Yasuhiro Arai and Tanaka, {Ken Ichiro} and Hironori Ushijima and Wataru Tomisato and Shinji Tsutsumi and Mayuko Aburaya and Tatsuya Hoshino and Kazumi Yokomizo and Keitarou Suzuki and Takashi Katsu and Tomofusa Tsuchiya and Tohru Mizushima",
year = "2005",
month = "9",
doi = "10.1007/s10620-005-2909-x",
language = "English",
volume = "50",
pages = "1641--1646",
journal = "American Journal of Digestive Diseases",
issn = "0002-9211",
publisher = "Springer New York",
number = "9",

}

TY - JOUR

T1 - Low direct cytotoxicity of nabumetone on gastric mucosal cells

AU - Arai, Yasuhiro

AU - Tanaka, Ken Ichiro

AU - Ushijima, Hironori

AU - Tomisato, Wataru

AU - Tsutsumi, Shinji

AU - Aburaya, Mayuko

AU - Hoshino, Tatsuya

AU - Yokomizo, Kazumi

AU - Suzuki, Keitarou

AU - Katsu, Takashi

AU - Tsuchiya, Tomofusa

AU - Mizushima, Tohru

PY - 2005/9

Y1 - 2005/9

N2 - Prodrugs of non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for clinical purposes because they are not harmful to the gastrointestinal mucosa. We recently showed that NSAIDs have direct cytotoxicity in NSAID-induced gastric lesions. We show here that under conditions where the NSAIDs indomethacin and celecoxib clearly induce cell death, an NSAID prodrug, nabumetone, and its active metabolite 6-methoxy-2-naphthylacetic acid (6MNA), did not have such effects. Moreover, nabumetone and 6MNA exhibited much lower membrane permeabilizing activities than did indomethacin and celecoxib. We recently reported that when an orally administered NSAID was used in combination with a low dose of intravenously administered indomethacin, the severity of gastric lesions produced in rats depended on the cytotoxicity of the orally administered NSAID. Using a similar protocol, we show here that gastric lesions were produced when the orally administered NSAID was celecoxib, but not when nabumetone was used. We thus propose that the low direct cytotoxicity of nabumetone observed in vitro is maintained in vivo, and that the use of nabumetone does not harm the gastric mucosa.

AB - Prodrugs of non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for clinical purposes because they are not harmful to the gastrointestinal mucosa. We recently showed that NSAIDs have direct cytotoxicity in NSAID-induced gastric lesions. We show here that under conditions where the NSAIDs indomethacin and celecoxib clearly induce cell death, an NSAID prodrug, nabumetone, and its active metabolite 6-methoxy-2-naphthylacetic acid (6MNA), did not have such effects. Moreover, nabumetone and 6MNA exhibited much lower membrane permeabilizing activities than did indomethacin and celecoxib. We recently reported that when an orally administered NSAID was used in combination with a low dose of intravenously administered indomethacin, the severity of gastric lesions produced in rats depended on the cytotoxicity of the orally administered NSAID. Using a similar protocol, we show here that gastric lesions were produced when the orally administered NSAID was celecoxib, but not when nabumetone was used. We thus propose that the low direct cytotoxicity of nabumetone observed in vitro is maintained in vivo, and that the use of nabumetone does not harm the gastric mucosa.

KW - Gastric lesions

KW - Gastric mucosal cells

KW - Membrane permeabilization

KW - Nabumetone

UR - http://www.scopus.com/inward/record.url?scp=23944443835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944443835&partnerID=8YFLogxK

U2 - 10.1007/s10620-005-2909-x

DO - 10.1007/s10620-005-2909-x

M3 - Article

VL - 50

SP - 1641

EP - 1646

JO - American Journal of Digestive Diseases

JF - American Journal of Digestive Diseases

SN - 0002-9211

IS - 9

ER -